Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)

2023-509257-31-00 Protocol ION269-CS1 Human pharmacology (Phase I) - First administration to humans Ended

Start 12 Feb 2025 · End 21 Aug 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol ION269-CS1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 30
Countries 1
Sites 2

Alzheimer’s Disease in Individuals with Down Syndrome

Key facts

Sponsor
Ionis Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
12 Feb 2025 → 21 Aug 2025
Decision date (initial)
2024-10-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-509257-31-00
WHO UTN
U1111-1306-9498

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alzheimer’s Disease in Individuals with Down Syndrome

VersionLevelCodeTermSystem organ class
20.0 LLT 10013616 Down's syndrome 10010331
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Ionis Pharmaceuticals Inc.

Sponsor organisation
Ionis Pharmaceuticals Inc.
Address
2855 Gazelle Court
City
Carlsbad
Postcode
92010-6670
Country
United States

Scientific contact point

Organisation
Ionis Pharmaceuticals Inc.
Contact name
Global Regulatory Affairs at Ionis Pharmaceuticals, Inc.

Public contact point

Organisation
Ionis Pharmaceuticals Inc.
Contact name
Global Regulatory Affairs at Ionis Pharmaceuticals, Inc.

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 7 2
Rest of world
United States, United Kingdom
23

Investigational sites

Spain

2 sites · Ended
Hospital De La Santa Creu I Sant Pau
Neurology, Carrer De San Quinti 89, 08041, Barcelona
Fundacion CITA Alzheimer
Neurology, Pasealeku Mikeletegi 71, 20009, Donostia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-02-12 2025-02-12

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-16 Spain Acceptable with conditions
2024-10-10
2024-10-10
2 SUBSTANTIAL MODIFICATION SM-1 2024-10-30 Spain Acceptable with conditions 2024-12-05
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-12-06 Spain Acceptable with conditions 2024-12-06
4 SUBSTANTIAL MODIFICATION SM-2 2024-12-11 Spain Acceptable with conditions 2025-02-04
5 NON SUBSTANTIAL MODIFICATION NSM-2 2025-03-06 Spain Acceptable with conditions 2025-03-06
6 NON SUBSTANTIAL MODIFICATION NSM-3 2025-03-18 Acceptable with conditions